Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × olaparib × Head & Neck × Clear all

Phase

Status

Active not recruiting 4 Completed 3 Unknown 2 Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 21 Breast 18 Gastrointestinal 11 Genitourinary 9 Thoracic 6 Other solid neoplasm 6 CNS 6 Tumor-Agnostic 3 NET 3 Endocrine 3 Plasma cell 2 Lymphoid 2 Sarcoma 1 Other hematologic neoplasm 1 Head & Neck 1 Dermatologic 1 Classical hematology 1

Conditions

Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 87 pembrolizumab 75 Radiotherapy 42 Carboplatin 38 Radiotherapy, Intensity-Modulated 34 Magnetic Resonance Spectroscopy 34 toripalimab 32 Gemcitabine 27 Docetaxel 26 Cetuximab 26 Specimen Handling 25 Paclitaxel 23 Surgical Procedures, Operative 20 Fluorouracil 20 Drug Therapy 20 Blood Specimen Collection 20 Biopsy 19 Radiation 18 Nivolumab 18 camrelizumab 14 Chemoradiotherapy 14 Platinum 13 tislelizumab 11 X-Rays 11 Surveys and Questionnaires 11 Capecitabine 11 1,2-diaminocyclohexaneplatinum II citrate 11 spartalizumab 10 Standard of Care 10 130-nm albumin-bound paclitaxel 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04825990 2022-04-07

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡